Validation of In Vitro Diagnostic applications of the CETSA method

Important results from the project

Development of CETSA assay formats to enable diagnostic tools to optimise the treatment of the individual patient. The CETSA assays shall quantify Target Engagement to enable selection of the right dose of medicine for the patient. Such CETSA assays will also make it possible to validate existing and novel biomarkers for relevant profiling of novel and existing medicine i samples from the individual patient. After careful validation in clinical studies it will be possible to select the best suited medicine to optimise treatment outcome in all patients.

Expected long term effects

The results from the executed studies will facilitate the development of novel target cancer drugs. Analysis of tissues and in vitro cell cultures has increased our knowledge and understanding of the translation between dose, exposure, target engagement and efficacy of the investigated drugs. Development of CETSA test formats and analysis tools has increased the commercial potential for the CETSA method. The results will also have a big impact on the continued development of in vitro diagnostic CETSA assay formats.

Approach and implementation

The collaboration between the medical expertise at the Karolinska University Hospital, the basic science faculty at the Karolinska Institute and other Swedish SME´s have increased Pelago Bioscience AB´s knowledge and prerequisites for the continued development and use of the CETSA method. We have focused on meticulous and careful laboratory work to improve the method as an analytical tool, which now yields positive results in quality, capacity utility for our customers.